---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-008096"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2022-05-10T23:59:59+00:00"
generated_at: "2026-06-25T21:44:09.694212+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Reneo Q1 net loss $13.0M; STRIDE enrollment 50% done; LC-FAOD data in July 2022

## Summary
- Net loss of $13.0M ($0.53/share) vs $7.2M loss ($3.48/share) in Q1 2021.
- Cash, equivalents and short-term investments of $138.7M as of March 31, 2022.
- R&D expenses rose to $9.3M from $5.5M, driven by STRIDE and FORWARD studies.
- Enrolled 100th patient in STRIDE Phase 2b PMM trial; target enrollment 200.
- Phase 1b and FORWARD natural history study results in LC-FAOD expected July 2022.

## SEC filing metadata
- accession: 0001558370-22-008096
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2022-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000155837022008096/0001558370-22-008096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000155837022008096/rphm-20220510x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-008096
- JSON: https://secwatch.observer/filing/0001558370-22-008096.json
- Plain text: https://secwatch.observer/filing/0001558370-22-008096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.